Description of Invention: This technology describes monoclonal antibodies against mouse chemokine (C-X-C motif) ligand 9 (CXCL9), also known as Monokine induced by gamma interferon (Mig). CXCL9 is a secreted protein that functions to attract white cells and increased expression of CXCL9 has been linked to several diseases. The inventors at the NIH generated over 100 anti-mouse CXCL9 antibodies from a CLXL9/Mig knockout mouse and further characterized several antibodies to show neutralization of CXCL9. As such, these antibodies could be used to measure concentrations of mouse CLXL9 in laboratory samples and block the activity of CXCL9 in injected mice. These antibodies are suitable for ELISA and Western blot. The antibodies have not been tested in flow cytometry or immunohistochemistry, but may also be useful for these applications.
ELISA assays for detection and measurement of CXCL9.
Neutralization of CXCL9 activity in mouse models and in vitro assays to study the role of CXCL9 in immune response and disease.
Advantages: Can be used in mice without eliciting endogenous antibodies reacting against the injected anti-CXCL9.
Development Status: The technology is currently in the pre-clinical stage of development.
Inventors: Joshua M Farber (NIAID) Hongwei H Zhang (NIAID)
Patent Status: HHS, Reference No. E-198-2009/0
Research Tool -- Patent protection is not being pursued for this technology.
Licensing Status: Available for licensing.
Portfolios: Devices/Instrumentation Cancer Cancer - Research Materials Internal Medicine Internal Medicine - Diagnostics Internal Medicine - Research Materials
For Licensing Information Please Contact: Whitney Hastings NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-451-7337 Fax: 301-402-0220